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Arterial Stiffness Can Be Modulated by Pressure-Independent
Mechanisms in Hypertension
Luca Faconti, MBBS/BSc; Bushra Farukh, MSc; Ryan McNally, MPharm; Andrew Webb, PhD; Phil Chowienczyk, BSc, FRCP
Background-—Effects of short-term interventions on large-artery stiffness assessed by pulse wave velocity (PWV) have mainly been
explained by concomitant changes in blood pressure (BP). However, lower body negative pressure, which increases sympathetic
activity and has other hemodynamic effects, has a speciﬁc effect on PWV in healthy volunteers.
Methods and Results-—We examined effects of lower-limb venous occlusion (LVO), a similar intervention to lower-body negative
pressure that reduces BP but increases sympathetic activity and device-guided breathing (DGB), which reduces both BP and
sympathetic activity, on PWV in patients with essential hypertension (n=70 after LVO, n=45 after DGB and LVO in random order).
The short-acting calcium channel antagonist nifedipine was used as a control for changes in BP. LVO produced a small but
signiﬁcant reduction in mean arterial pressure of 1.8 (95% CI 0.3–3.4) mm Hg. Despite this, aortic and carotid-femoral PWV
increased during LVO by 0.8 (0.2–1.4) m/s and 0.7 (0.3–1.05) m/s, respectively. DGB reduced PWV by 1.2 (0.9–1.4) m/s, to a
greater extent than did nifedipine 10 mg (reduction of 0.7 [0.1–1.3] m/s, P<0.05 compared with reduction during DGB). This
occurred despite a greater decrease in BP with nifedipine compared with DGB.
Conclusions-—Arterial stiffness can be modulated independently of BP over the short term. The mechanism could involve
alterations in sympathetic activity or other as yet uncharacterized effects of LVO and DGB. ( J Am Heart Assoc. 2019;8:e012601.
DOI: 10.1161/JAHA.119.012601.)
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A ortic and large artery stiffness is a major determinantof the pulsatile component of blood pressure (BP) and
of cardiovascular risk.1–3 It is determined by an interplay
between the steady-state component of BP (mean arterial
blood pressure, MAP) that acts to distend the arterial wall,
and properties of the wall that determine its stress–strain
relationship.4 This, in turn, is thought to relate mainly to the
mechanical properties of the extracellular matrix rather than
being inﬂuenced by the tone of vascular smooth muscle.5
Vascular tone does inﬂuence arterial stiffness in muscular
arteries6–9 (where it can be assessed independently of MAP)
but its inﬂuence is difﬁcult to assess in the aorta because
interventions to alter vascular tone usually have systemic
effects on MAP. Previous studies have reported conﬂicting
results regarding a possible BP-independent role of the
autonomic nervous system in the regulation of arterial
stiffness.10–15 The interpretation of these studies has been
limited by concurrent change in BP which, in almost all
cases, has been in the same direction as the change in
arterial stiffness. In the present study, we examined the
effects of interventions that activate and deactivate the
sympathetic nervous system on aortic and large artery pulse
wave velocity (PWV) in patients with essential hypertension.
We used lower-limb venous occlusion (LVO) that causes
reﬂex sympathetic activation (similarly to low-level lower-
body negative pressure16), device-guided breathing (DGB) to
reduce sympathetic activity (SA),17 and a calcium channel
blocker that acts predominantly on the microvasculature to
provide a control for change in MAP. These interventions
were expected to reduce BP but to have differing effects on
PWV that would allow a speciﬁc (BP-independent) effect on
PWV to be elicited.
Methods
Study Population
Anonymized individual patient data used in this study will be
made available to academic investigators through the
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corresponding authors. Participants were consecutively con-
senting subjects attending the hypertension clinics at Guy’s
and St Thomas’ Hospital over the period August 2017 to
December 2018 who were invited to take part in 1 of the 2
studies described below. Hypertension was diagnosed on the
basis of previous treatment and/or daytime systolic ambula-
tory BP (or home BP averaged ≥7 days) of >135 mm Hg
systolic or >85 mm Hg diastolic, according to current guide-
lines.18 Pregnant women were excluded from the study, as
were those in whom the clinical history or investigations
suggested a presence of secondary hypertension. Patients
with moderate or severe valvular disease and/or those with
sustained nonsinus arrhythmias were also excluded. The
study was approved by the London Westminster Research
Ethics Committee, and written informed consent was
obtained from all patients. The following hemodynamic
measurements were obtained in addition to measurement of
height, weight, and routine biochemistry.
BP and Pulse Wave Analysis
Participants were asked to abstain from caffeine, alcohol, and
strenuous exercise for at least 24 hours before hemodynamic
measurements, which were conducted in a temperature- and
light-controlled laboratory following voiding. After 15 minutes
of supine rest, BP and heart rate (HR) were recorded in the
brachial artery using a validated oscillometric technique
(HEM-705CP, Omron Corp, Kyoto, Japan). The average of 3
consecutives readings of systolic BP (SBP) and diastolic BP
(DBP) was used for the analysis. Pulse wave analysis of the
radial artery (SphygmoCor, AtCor Medical, Sydney, Australia)
was performed for estimation of the central aortic pressure
from the radial artery using the SphygmoCor generalized
transfer function, with calibration from brachial BP. Measure-
ments were performed by a single operator in triplicate with
an in-device quality rating ≥85% required for all the record-
ings, which were then averaged for analysis.
Pulse Wave Velocity
Aortic PWV (aoPWV) was estimated with pulsed Doppler
(Philips Epiq 7 ultrasound system, Koninklijke Philips N.V.,
Amsterdam, The Netherlands) by measuring the time taken
by the pulse wave to travel along the thoracic aorta from the
aortic arch to the abdominal aorta.19,20 Transit time was
estimated by the difference between the R-wave of a
simultaneously recorded ECG and the foot of the ﬂow wave
recorded at proximal and distal sites. The path length
between the 2 insonated sites was estimated from surface
markings (sternal notch to xiphoid process) and aoPWV
calculated as the quotient of path length and transit time.
Measurements were made by a single operator, and the
average of 2 consecutive measurements was used for the
analysis. Carotid–femoral pulse wave velocity (cfPWV) was
measured from ECG-referenced carotid and femoral tono-
metric recordings obtained using the SphygmoCor device.21
Measurements were made by a single operator and the
average of 2 consecutive measurements was used for the
analysis.
Heart Rate Variability
HRV (Schiller Medilog AR12plus, United States) was assessed
in the frequency domain as previously described.22 With the
patient lying in the supine position, short-term recordings
were performed after 15 minutes of rest and then repeated
every 3 minutes. The spectral proﬁle of human HRV contains
3 components, with frequencies at rest centered at 0.00 Hz
(very low frequency), 0.10 Hz (LF=low frequency), and around
the respiratory rate (HF=high frequency), respectively. HF and
LF components are inﬂuenced by parasympathetic and SA,
respectively,23 and the ratio of LF/HF is inﬂuenced by
sympathetic relative to parasympathetic activity.24 However,
it has been stressed by many authors that HRV and the LF/HF
ratio is not a measure of SA.25,26
Study Protocols
Study 1: Effects of LVO on BP and PWV
LVO is a novel technique developed to create an isolated
reduction of preload within the physiological range using low-
pressure thigh cuff inﬂation. Brieﬂy, pneumatic leg cuffs are
applied around the thighs and inﬂated to a supradiastolic,
subsystolic brachial BP. This causes venous pooling in the
legs with a decrease in cardiac output and reﬂex sympathetic
activation but with only minimal effects on BP.27 Baseline
measurements of BP, pulse wave analysis (PWA), and aoPWV
Clinical Perspective
What Is New?
• Stiffness of large elastic arteries can be modiﬁed indepen-
dently of blood pressure in subjects with hypertension.
• The mechanism could involve alterations in sympathetic
activity regulating vascular smooth muscle tone in large
elastic arteries.
What Are the Clinical Implications?
• Dissociation of arterial stiffness and blood pressure has
potential implications for therapeutics since interventions
that directly reduce sympathetic activity may have addi-
tional beneﬁts to the extent that would be achieved by the
reduction in blood pressure.
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were obtained after 15 minutes of supine rest and repeated
after 5 minutes of continuous cuff inﬂation (with cuffs inﬂated
for a total of 10 minutes). In a subsample of subjects (n=23)
cfPWV was also measured before and after LVO.
Study 2: Comparative effects of LVO, DGB, and
nifedipine on BP, HRV, and PWV
In this study we compared effects of LVO and DGB on
cfPWV. PWV was measured over the carotid–femoral route
rather than over the thoracic aorta because insonation of
the abdominal aorta tends to disturb and is confounded by
the deeper breathing induced by DGB. Measurements of BP,
PWA, cfPWV, and HRV were performed at baseline and after
LVO (as described in study 1) and DGB (Resperate, InterCure
Ltd., Lod, Israel) with these 2 interventions performed in
random order. The DGB device consists of a respiration
sensor and headphones, which provides feedback to the
patient. During a session of DGB, the breathing rate and
pattern are analyzed and feedback sounds generated to
allow the expiratory phase of each breath to be prolonged
and respiratory rate to be reduced to <10 breaths/min.28
This produces an immediate suppression of muscle
sympathetic nerve activity and has a modest effect on
lowering BP.29 In a subsample of participants (n=19), after
performing DGB and LVO as previously described, nifedipine
10 mg was administered orally. With the patient still lying in
the supine position, hemodynamic measurements were
repeated over a period of 30 to 60 minutes after adminis-
tration of nifedipine when its effects were close to maximal.
Nifedipine is a short-acting dihydropyridine calcium antago-
nist that reduces BP and causes a reﬂex activation of muscle
sympathetic nerve activity.17
Sample Size and Statistics
Sample size was estimated from previous studies on the
repeatability of PWV. A sample size of n>70 for study 1 was
chosen to provide >90% power for a type I error rate 0.05 to
detect a change in aoPWV >0.5 m/s. Sample size for study 2
(n>40) was chosen to give similar power to detect a difference
in PWV between interventions of 0.5 m/s (the within-subject
SD of cfPWV being less than that of aoPWV). Statistical
analysis was performed using SPSS24 (IBM). Subject charac-
teristics and results are expressed as meanSD or mean (95%
CI). Differences in means before and after interventions were
analyzed using Student’s paired t test for normally distributed
variables, or Wilcoxon rank sum test for not normally
distributed variables. P<0.05 was considered statistically
signiﬁcant and all tests were 2-tailed. Categorical variables
were compared by v2 test. Pearson’s product-moment coef-
ﬁcient was used to explore correlations between variables.
Table 1. Characteristics of the Study Population
Study 1 (n=70) Study 2 (n=45)
Age, y 45.512.9 46.812.64
Sex (% male) 61.4 62.2
Race
White (%) 39.7 35.6
Black, % 39.7 46.7
Others, % 20.6 17.8
BMI, kg/m2 28.04.55 28.34.47
Diabetes mellitus, % 7.1 6.8
Dyslipidemia, % 22.9 22.7
CV event, % 5.7 6.8
Creatinine, lmol/L 97.8744.80 89.7423.81
HbA1c, mmol/mol 39.728.21 40.3312.56
Total cholesterol, mmol/L 4.830.85 4.751.19
Drug treatment, % 62.9 62.2
ACE, ARB, % 37.1 31.1
CCB, % 34.3 40
BB, % 10 11.1
Diuretic, % 21.4 28.9
Doxazosin, % 5.7 11.1
Other treatment, % 5.7 6.7
Values are meansSD or percentages. ACE indicates angiotensin-converting-enzyme
inhibitor; ARB, angiotensin II receptor blocker; BB, b-blocker; BMI, body mass index; CCB,
calcium channel blocker; CV event, previous cardiovascular event; HbA1c, glycosylated
hemoglobin.
Table 2. Study 1: Effects of LVO on Hemodynamics and
Pulse Wave Velocity (n=70)
Variable Baseline LVO P Value
SBP, mm Hg 142.1517.05 138.0617.04 <0.001
DBP, mm Hg 89.3412.84 89.8512.54 0.380
HR, bpm 78.1621.88 77.2921.30 0.221
cSBP, mm Hg 124.52119.09 121.3017.54 0.001
cDBP, mm Hg 92.2614.67 92.1514.21 0.883
MAP, mm Hg 103.9716.67 102.1415.68 0.021
cAP, mm Hg 8.416.68 6.556.06 0.001
cPP, mm Hg 38.3610.32 34.478.89 <0.001
cAIx, % 20.4713.71 17.9514.49 0.036
aoPWV, m/s 7.232.29 8.083.66 0.005
cfPWV, m/s 9.181.98 9.872.60 0.001
aoPWV indicates aortic pulse wave velocity; bpm, beats per minute; cAIx, central
augmentation index; cAP, central augmentation pressure; cDBP, central diastolic blood
pressure; cfPWV, carotid–femoral pulse wave velocity; cPP, central pulse pressure;
cSBP, central systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate;
LVO, lower-limb venous occlusion; MAP, mean arterial pressure; SBP, systolic blood
pressure.
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Results
Study 1: Effects of LVO on BP and PWV
Characteristics of hypertensive patients (n=70) are reported in
Table 1. Patients were predominantly young to middle-aged men
and women,most of whomwere overweight, and a relatively high
proportionwere of black ethnicity in linewith the demographics of
referrals to the hypertension service in southeast London. Forty-
four patients were on pharmacological treatment with 1 or more
antihypertensive drugs. LVO had no signiﬁcant effect on HR or
DBP but produced a small but signiﬁcant decrease in SBP of 3.4
(95% CI 1.6–5.2) mm Hg as well as a reduction inMAP (reduction
of 1.8 [0.3–3.4] mm Hg, central SBP and central pulse pressure
(reduction of 3.9 [2.1–5.7] mm Hg, Table 2). Despite the
reduction in MAP, aoPWV increased during LVO by 0.8 (0.3–
1.4) m/s. A similar increase of 0.7 (0.3–1.0) m/s was seen in
cfPWV. The dissociation of change in cfPWV with BP components
applied not only to MAP but to peripheral and central SBP.
Study 2: Effects of LVO and DGB on BP, HRV, and
cfPWV
Forty-ﬁve patients were recruited in study 2, and their character-
istics were similar to those in study 1 (Table 1). As in study 1, LVO
had no signiﬁcant effect on HR or DBP but produced small but
signiﬁcant decreases in SBP andMAP of 3.9 (2.1–5.6)mm Hg and
1.3 (0.2–2.5) mm Hg, respectively (Table 3, Figure). cfPWV
increased during LVO to a similar extent as in study 1: by 1.0
(0.7–1.3) m/s. HRV analysis showed a signiﬁcant increase in the
log ratio LF/HF of 0.14 (0.09–0.18) during LVO. Compared with
LVO,DGBproducedamoremarkeddecrease inBPwith reductions
in SBP and MAP of 10.5 (8.6–12.4) mm Hg and 6.8 (5.4–8.2)
mm Hg, respectively, as well as signiﬁcant reductions in HR and
DBP of 3.9 (2.2–5.7) beats per minute and 4.7 (3.3–6.1) mm Hg,
respectively. Log LF/HF decreased by 0.12 (0.06–0.17). cfPWV
was reduced by 1.2 (0.9–1.4) m/s during DGB. When comparing
effects of DGB with nifedipine (n=19), nifedipine produced a
greater reduction in MAP (reduction of 13.4 [10.2–17.7] mm Hg,
P=0.009 comparedwith reduction duringDGB)with a tendency for
log LF/HF to increase rather than decrease so that the change in
log LF/HFafter nifedipinewas signiﬁcantly greater than that during
DGB (P=0.05, Table 3). Despite a comparatively greater reduction
in BP (MAP, SBP, and cSBP) by nifedipine, the decrease in cfPWV
was less than that observedwithDGB (0.5 [0.1–1.0]m/s;P=0.022
compared with reduction during DGB, Figure).
Discussion
This is the ﬁrst study, as far as we are aware, to show a
dissociation between change in PWV and change in BP in
Table 3. Study 2: Effects of LVO, DGB, and Nifedipine on Hemodynamics and Pulse Wave Velocity
Variable Baseline LVO DGB Nifedipine
All subjects (n=45)
SBP, mm Hg 146.3616.75 142.4915.89* 135.8215.28* 
DBP, mm Hg 88.389.53 89.0410.05 83.679.49* 
HR, bpm 70.1812.48 69.5112.13 66.2211.88* 
MAP, mm Hg 108.4111.08 107.0711.78 101.6110.82* 
cSBP, mm Hg 133.0916.10 129.5515.22* 124.4315.31* 
cfPWV, m/s 10.012.00 11.012.32† 8.831.71* 
HRV (logLF/HF) 0.310.28 0.440.27* 0.180.30* 
Subsample receiving nifedipine (n=19)
SBP, mm Hg 150.4412.01 146.0612.56* 138.1711.10* 133.1711.80*
DBP, mm Hg 89.838.77 90.118.91 84.399.15* 78.839.23*
HR, bpm 65.8911.15 65.5011.07 62.3311.95* 75.0612.58*
MAP, mm Hg 110.789.00 109.229.56 103.008.41* 97.339.70*
cSBP, mm Hg 136.4810.72 131.2611.0* 128.1110.77* 118.5711.08*
cfPWV, m/s 10.332.38 11.292.36* 9.041.84* 9.592.01†
HRV (logLF/HF) 0.350.29 0.510.28* 0.250.37* 0.420.33
bpm indicates beats per minute; cfPWV, carotid–femoral pulse wave velocity; cSBP, central systolic blood pressure; DBP, diastolic blood pressure; DGB, device-guided breathing; HF, high
frequency; HR, heart rate; HRV, heart rate variability; LF, low frequency; LVO, lower-limb venous occlusion; MAP, mean arterial pressure; SBP, systolic blood pressure.
*P<0.01 compared with baseline.
†P<0.05 compared with baseline.
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subjects with hypertension. Most acute interventions that
modulate cfPWV can be explained by their effects on
MAP,30,31 inﬂuencing distension of the arterial wall and hence
loading or unloading stiffer elements within the wall. Lack of a
speciﬁc effect on the wall has been attributed to the relatively
small amount of vascular smooth muscle within the wall of
large elastic arteries compared with muscular conduit arter-
ies.32,33 This study by contrast demonstrates a clear disso-
ciation between change in MAP and PWV during LVO, with an
increase in PWV despite a decrease in MAP. The dissociation
of change in cfPWV with BP components applied not only to
MAP but to peripheral and central SBP. While the increase in
PWV is modest, it is clinically signiﬁcant and is equivalent to
the change seen with age over a period of 5 to 10 years.34
Importantly, it is also seen when PWV is measured over the
elastic aorta as well as over the carotid–femoral region, thus
excluding an effect restricted only to more muscular regions
of the carotid–femoral pathway. LVO had no signiﬁcant effect
on HR and decreased pulse pressure as well as MAP, effects
that generally tend to reduce rather than increase PWV.35 One
explanation for the increase in PWV with LVO is the well-
recognized activation of SA produced by a reduction in venous
return (as evidenced indirectly in the present study by change
in HRV) acting to increase vascular smooth muscle tone.16,36
Previous interventional studies have reported conﬂicting
results regarding a possible BP-independent role of the
autonomic nervous system in the regulation of arterial
stiffness.10–15 A common limitation in most of these studies
was, however, the confounding effects of altered distending or
pulsatile BP. Our ﬁndings are in line with a recent study
conducted in healthy normotensive subjects using lower-body
negative pressure16 showing an increase in PWV despite no
brachial BP change. Lower-body negative pressure had
modest sympathoexcitatory effects conﬁrmed by increases
in muscle sympathetic nerve activity.16
Further evidence in the present study to support a BP-
independent effect on PWV is provided by the effects of
DGB,29 an intervention that has short-term effects to reduce
muscle sympathetic nerve activity. While the reduction in PWV
seen during DGB could have been explained by the concurrent
decrease in MAP, comparison with the effects of nifedipine
largely excludes this possibility. Nifedipine produced a smaller
decrease in PWV despite a larger drop in all BP components
(Figure). These observations would be consistent with an
effect on PWV mediated through modulation of SA, since
nifedipine is known to cause a reﬂex increase in SA.17 Taken
together, the effects of LVO and DGB demonstrate that cfPWV
and aoPWV can be changed independently of BP, and that the
mechanism of such dissociation could involve sympathetic
activation inﬂuencing the tone of smooth muscle in the aortic
wall.
There are several important consequences of these
observations. Previous studies have examined the pressure
dependence of aoPWV and cfPWV by modulating BP, under
physiological conditions of an intact autonomic nervous
system, and may have underestimated the true pressure
dependence of PWV because a drop in BP will tend to cause a
reﬂex activation of SA and hence attenuate the fall in PWV
and a rise in BP will do the opposite.37,38 This will not disrupt
the continuous relationship between PWV and MAP, but will
alter the slope of this relationship; a dissociation between
PWV and MAP will only be apparent for interventions such as
LVO that have opposing effects on SA and BP.
While the role of SA in mediating the BP-independent
changes in PWV remains speculative, such an inﬂuence of SA
on PWV would have implications for therapeutics. Beneﬁcial
effects of antihypertensive drugs that cause reﬂex sympa-
thetic activation could be offset by a rise in PWV as well as by
other mechanisms. Conversely, interventions that directly
Figure. Change from baseline in mean arterial
pressure (MAP, A), heart rate variability (HRV, B)
and carotid–femoral pulse wave velocity (cfPWV, C)
after lower-limb venous occlusion (LVO), device-
guided breathing (DGB), and nifedipine (10 mg).
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reduce SA may have additional beneﬁts to reduce PWV to a
greater extent than would be achieved by the reduction in
MAP. It is notable that 2 studies that have examined the
effects of peripheral a-adrenergic receptor blockade have
demonstrated a BP-independent reduction in measures of
PWV.39,40 While a-adrenergic receptor blockade may not be
effective in reducing adverse outcomes when compared with
other antihypertensive drugs,41 this may be because of
unopposed b-adrenergic activation, and combined a- and b-
blockade is thought to confer increased protection.42 In
studies of renal denervation, reduction of PWV to a greater
extent than can be explained by BP has been observed, which
would be consistent with a medium-term effect of SA on
PWV.43,44
Limitations
There are several important limitations to our study. We
examined hypertensive patients, the majority of whom were
on treatment; further studies will be required to determine
whether the effects of LVO and DGB differ between
normotensive and hypertensive subjects and according to
hypertensive phenotype. Although a change in SA provides a
potential explanation for our ﬁndings of a dissociation of
cfPWV with BP after LVO and DGB, further interventional
studies will be required to establish this with certainty and to
distinguish whether these effects are directly related to action
on vascular smooth muscle or are mediated by other
hemodynamic changes or other mechanisms that we did
not capture in the present study. Reduction in cardiac
preload, for example, leads to a reduction in stroke volume
and while this would theoretically be expected to decrease
rather than increase cfPWV, we are not aware of any studies
that have examined the inﬂuence of stroke volume directly.
DGB could have effects that are mediated through alterations
in arterial blood gases, although we are not aware of any
studies that have demonstrated such an effect. HRV is an
indirect measure of SA and is inﬂuenced by other factors
including vagal tone and respiratory rate, and thus may not
reﬂect sympathetic outﬂow. However, previous studies have
shown that muscle sympathetic nerve activity, a more direct
measure of SA, changes in parallel with the changes in HRV
that we observed in the present study.16,17,27 Lastly, we
examined only the immediate effects of sympathetic modu-
lation. Long-term effects will require further study.
Conclusions
Arterial stiffness can be modulated independently of BP over
the short term, possibly through alterations in SA. Interven-
tional studies to examine effects of a reduction in SA on PWV
above those expected by a reduction in BP alone are required
to conﬁrm the mechanism of BP-independent modulation of
PWV.
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